Shots:

• 23andMe to receive a one-time fee of $50M to extend the period along with royalty on its immuno-oncology Ab collaboration program GSK’608 targeting CD96. GSK will be responsible for the development of GSK’608’ in clinical trials including development costs
• GSK has exercised its option to extend an exclusive target discovery period of collaboration for an additional year to July 2023 to discover & validate novel drug targets using 23andMe’s genetic & health survey database
• In July 2018, GSK collaborated with 23andMe & included 4 yr. exclusive target discovery period. The CD96 program is being evaluated in P-I clinical trial in combination with GSK’s dostarlimab

Ref: Globe Newswire | Image: GSK